Yew Bio-Pharm Group, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended of September 30, 2017. For the quarter, the company’s total revenues decreased 21.2% to $11.6 million from $14.7 million a year ago. Net income decreased 43.1% to $614,407 from $1.1 million in the same quarter last year. Earnings per diluted share were $0.01, as compared to $0.02 for the same quarter of last year. Income from operations was $489,000 compared to $1,119,515 a year ago. Income before income taxes was $615,017 compared to $1,080,538 a year ago. For the nine months, the company’s total revenues decreased 10.9% to $35.0 million from $39.3 million a year ago. Net income increased 221.2% to $11.0 million from $3.4 million for the same period last year. Earnings per diluted share were $0.20, as compared to $0.07 for the same period last year. Income from operations was $11,000,325 compared to $3,505,580 a year ago. Income before income taxes was $11,040,434 compared to $3,437,145 a year ago. Net cash used in operating activities was $953,991 compared to net cash provided by operating activities was $361,987 a year ago. Purchase of land use rights and yew forest assets was $793,662 compared to $7,742 a year ago.